Pentwater Capital Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Pentwater Capital Management’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-46,000	Closed	-$995K	–	259
2021 Q3	$995K	Sell	46,000 -4,000	-8%	-$110K	0.01%	189
2021 Q2	$1.47M	Hold	50,000	–	–	0.01%	183
2021 Q1	$1.38M	Hold	50,000	–	–	0.01%	203
2020 Q4	$1.68M	Sell	50,000 -11,084	-18%	-$337K	0.02%	139
2020 Q3	$1.47M	Sell	61,084 -4,916	-7%	-$115K	0.02%	138
2020 Q2	$1.53M	Buy	+66,000	New	+$1.31M	0.03%	89

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Pentwater Capital Management's CALT Position: Q4 2021 in Review

Pentwater Capital Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2021, closing a stake of 46,000 shares — an estimated $995K sold.

Pentwater Capital Management first reported a position in CALT in Q2 2020 and held it in 6 quarters. The position peaked at $1.68M in Q4 2020. 17 funds tracked by Wall St. Rank hold CALT as of Q4 2021.

Pentwater Capital Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2021 after selling out during the quarter.
Pentwater Capital Management sold 46,000 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2021, an estimated $995K.
Pentwater Capital Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 6 quarters.
Pentwater Capital Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $1.68M in Q4 2020.
17 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2021.

Based on Pentwater Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.